Advertisement
"We are very pleased to have the Chinese University of Hong Kong as acustomer as we extend our reach in Asia," said Julie Bryant, VP businessdevelopment. "Hong Kong is a very sophisticated market with top notchresearchers in oncology and other key diseases, and we are glad that the CUHKgroup has chosen MetaCore. Disease area specific content is one of ourimportant development goals for the next 3 years."
Advertisement
About GeneGo
GeneGo develops systems biology technology for life science research. Theoriginal computational MetaDiscovery(TM) platform allows an integration andexpert analysis of different kinds of experimental data (mRNA expression,proteomics, metabolomics, microRNA assays and other phenotypic data) andrelevant bioactive chemistry (metabolites, drugs, other xenobiotics) withinthe framework of curated biological pathways and networks. GeneGo's flagshipproduct, MetaCore 4.6(TM), assists pharmaceutical scientists in the areas oftarget selection and validation, identification of biomarkers for diseasestates and toxicology. The second product, MetaDrug 4.6(TM) is designed forprediction of human metabolism, toxicity and biological effects for novelsmall molecules compounds. MetaBase(TM) represents the knowledge base forMetaCore. For more information, please visit the company's web site athttp://www.genego.com
MetaCore(TM), MetaBase(TM) MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM),MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo,Inc.
SOURCE GeneGo
